GSC and pneumocystosis: CRISPR Nad4 and Gsc1 results for serum identified patients who were PCP positive with 93.3% and 60.0% sensitivity, respectively, and 91.7% specificity, which also exceeded the performance (26.7% sensitivity / 91.7% specificity) of the matching RT-qPCR Nad4 results (Figure 5E, Table 4, and Supplemental 6B).